Using RNA Analytics, Bioinformatics, and Machine Learning/AI
AMPEL Genomic Platform (AGP®) and
genomic blood or biopsy tests for patients:
Evaluate disease status
Identify molecular pathways
Predict drug options
Precise Clinical Care Solutions
AMPEL Genomic Platform (AGP®), Bioinformatic Tools and Machine Learning Algorithms (AI/ML)
Step 1:
Create A Genomic Fingerprint
Comprehensive RNA analytics of gene expression from blood or biopsy to determine disease activity, molecular pathways and drug options.
Step 2:
Analyze The Fingerprint With ML/AI
Covers >95% of all known genes and is disease agnostic.
Step 3:
Provide Decision Making Support
Identification of patient’s immune status, provides decision support for most appropriate treatment options.
Step 4:
Market ready and Reproducible
First-in-class CLIA-certified gene-based Lab Developed Test (LDT).
Key Stats
Lead product LuGENE® expected Q2 2023. DermaGENE® expected Q1 2024.
Products for other indications available for partnering.
95%
coverage of all known genes and is disease agnostic
20,000+
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus
35+
technology patents filed & pending with the freedom to operate
20+
pharma customers validate the technology
5+
additional autoimmunity products in development
About the Founders
Peer-Reviewed Publications
Published in Internationally Recognized High Impact Journals
Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients
Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases
Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus
Deconvoluting the heterogeneity of SLE: The contribution of ancestry
Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries
COVID-19 Patients Exhibit Unique Transcriptional Signatures Indicative of Disease Severity
Medelian Randomization and Pathway Analysis Demonstrate Shared Genetic Associations Between Systemic Lupus Erythematosus and Coronary Artery Disease
Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus
Molecular endotypes of type 1 and type 2 SLE
Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
